Analysis of the response and toxicity to gefitinib of non-small cell lung cancer

Anticancer Research

Volumn 25, Issue 1 B, 2005, Pages 435-441

  Konishi, Jun ^a,f   Yamazaki, Koichi ^a,f   Kinoshita, Ichiro ^b,f   Isobe, Hiroshi ^c,f   Ogura, Shigeaki ^d,f   Sekine, Satoko ^d,f   Ishida, Takashi ^e,f   Takashima, Riou ^a,f   Nakadate, Megumi ^a,f   Nishikawa, Shyu ^a,f   Hattori, Takeshi ^a,f   Asahina, Hajime ^a,f   Imura, Mikado ^a,f   Kikuchi, Eiki ^a,f   Kikuchi, Junko ^a,f   Shinagawa, Naofumi ^a,f   Yokouchi, Hiroshi ^a,f   Munakata, Mitsuru ^d,f   Dosaka Akita, Hirotoshi ^b,f   Nishimura, Masaharu ^b,f  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c HOKKAIDO CANCER CENTER   (Japan)

^d SAPPORO CITY GENERAL HOSPITAL   (Japan)

^e FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^f Hokkaido Lung Cancer Clinical Research Group   (Japan)

Author keywords

Gefitinib; Non small cell lung cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PROTEIN TYROSINE KINASE;

ADULT; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; FEMALE; HUMAN; INTERSTITIAL PNEUMONIA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; RASH; SMOKING HABIT; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; QUINAZOLINES; RETROSPECTIVE STUDIES; SEX FACTORS; SMOKING; TIME FACTORS; TREATMENT OUTCOME;

EID: 20144388909     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Ginsberg RJ, Yokes EE and Raben A: Non-small cell lung cancer. In: De Vita VT, Hellmann S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology. Ed. 6, Philadelphia, Lippincott-Raven Publishers 858-910, 2001.
2. Bunn PA: Treatment of advanced non-small-cell lung cancer with two-drug combinations. J Cin Oncol 20: 3565-3567, 2002.
3. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer-A meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 311: 899-909, 1995.
4. Grilli R, Oxyman AD and Julian JA: Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? J Clin Oncol 11: 1866-1872, 1993.
5. Shepherd FA, Fossella FV, Lynch T, Arm JP, Rigas JR and Kris MG: Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: a view of two phase III trials. Semin Oncol 28: 4-9, 2001.
6. Fossella FV, De Vore R, Kerr RN, Crawford J, Natale RR, Dunphy F et al: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18: 2354-2362, 2000.
7. Pavelic K, Banjac Z, Pavelic J and Spavebti S: Evidence for a role of EGF receptor in the progression of human lung carcinoma. Anticancer Res 13: 1133-1137, 1993.
8. Fujino S, Enokibori T, Tezuka N, Asada Y, Inoue S, Kato H et al: A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer. Eur J Cancer 324: 2070-2074, 1996.
9. Baselga J: New technologies in epidermal growth factor receptor-targeted cancer therapy. Signal 1: 12-21, 2000.
10. Wells A: The epidermal growth factor receptor (EGFR): a new target in cancer therapy. Signal 1: 4-11, 2000.
11. Woodburn JR: The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82: 241-250, 1999.
12. Lawrence DS and Niu J: Protein kinase inhibitors: the tyrosine-specific protein kinases. Pharmacol Ther 77: 81-114, 1998.
13. Herbst RS, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Baselga J et al: Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 20: 3815-3825, 2002.
14. Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG et al: Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20: 4292-4302, 2002.
15. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21: 2237-2246, 2003.
16. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. JAMA 290: 2149-2158, 2003.
17. Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y et al: Severe acute interstitial pneumonia and gefitinib. Lancet 361: 137-139, 2003.
18. Histological Typing of Lung and Pleural Tumors, Ed 3. International Histological Classification of Tumours, World Health Orgnization. Geneva 1999.
19. American Joint Committee on Cancer: Lung. In: Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ (eds). Manual for Staging of Cancer. Philadelphia Lippincott 115-122, 1992.
20. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216, 2000.
21. Nishiwaki Y, Yano S, Tamura T, Nakagawa K, Kudoh S, Horai T et al: Subset analysis of data in the Japanese patients with NSCLC from IDEAL 1 study on gefitinib. Jpn J Cancer Chemother 31: 567-573, 2004.
22. Janne PA, Gurubhagavatula S, Yeap BY, Lucca J, Ostler P, Skarlin AT et al: Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, 'Iressa') on an expanded access study. Lung Cancer 44: 221-230, 2004.
23. Miller VA, Kris MG, Shah N, Patel J, Azzoli C, Gomez J et al: Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 22: 1103-1109, 2004.
24. Argiris A and Mittal N: Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer. Lung Cancer 43: 317-322, 2004.
25. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004.
26. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 129-39, 2004.